Participants in the study will take the medication in the form of a capsule, which is taken by mouth once a day. The study will monitor the response to the treatment over a period of time to see how well it works in managing the conditions. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment. The study aims to gather information on how the medication affects the body and its potential side effects.

By participating in this study, researchers hope to better understand the effectiveness of gandotinib in treating myeloproliferative neoplasms and to explore its potential as a treatment option for patients with these conditions. The study will help determine if this medication can improve the quality of life for those affected by these blood cancers.

The study is testing whether adding the experimental oral drug pelabresib (code name DAK539) to the approved oral medication ruxolitinib improves reduction of spleen size and relief of symptoms compared with taking ruxolitinib together with a placebo. The purpose of the study is to determine if the combination therapy provides a greater benefit than the standard treatment alone.

Participants will take the study tablets each day for several months. Throughout the trial they will undergo imaging tests, such as MRI or CT scan, to measure the size of the spleen, and they will complete simple questionnaires about how they feel. Regular health checks will be performed to monitor safety, and the study will continue for about a year to observe how the treatment works over time.

The purpose of this study is to evaluate the effect of pacritinib on bone marrow fibrosis, which is the scarring in the bone marrow. The study will examine whether the treatment can reduce the amount of scar tissue in the bone marrow after 52 weeks of treatment. Patients will take pacritinib daily, with a maximum daily dose of 400 milligrams, for up to 24 months. During the study, patients will have regular monitoring that includes bone marrow biopsies, which involve taking a small sample of bone marrow tissue for examination, and MRI scans, which are imaging tests that use magnetic fields to create detailed pictures of the inside of the body.

The study will also look at several other effects of the treatment, including changes in bone marrow fat content measured by MRI, improvements in red blood cell levels and the need for blood transfusions, changes in platelet counts, reduction in spleen size for those with an enlarged spleen, and changes in symptoms related to myelofibrosis. Additionally, the study will monitor genetic changes in the blood, measure various substances in the blood called cytokines, and track any side effects that occur during treatment. Patients will be asked to complete questionnaires about their symptoms throughout the study period.

The medication being studied, RVU120, comes in the form of capsules that are taken by mouth. The treatment can be given either alone or combined with other medications, depending on how the patient was treated in their previous study. The maximum daily amount that can be given is 150 milligrams, and treatment may continue for up to 5 months.

During the study, doctors will monitor how well patients tolerate the medication by checking for any side effects or health problems that may occur. The study will track how long patients can continue taking the medication before they need to stop treatment for any reason. This helps researchers understand both the long-term safety and effectiveness of RVU120 in treating these types of cancer.

The purpose of the study is to see if combining these two medications can help patients with Myelofibrosis who have not responded to previous treatments. Participants in the study will take these medications in the form of tablets. The study will monitor patients over time to see how their bodies react to the treatment and to check for any side effects. The study will also look at changes in symptoms and overall health during the treatment period.

Throughout the study, patients will have regular check-ups, which may include physical exams and tests like ECG (a test that checks the heart’s rhythm) and blood tests. The study aims to gather information on how the combination of Ruxolitinib and Roginolisib affects the size of the spleen, a common issue in Myelofibrosis, and whether it can improve symptoms and quality of life for patients. The trial will continue for several years to ensure comprehensive data collection and analysis.

Participants in the study will receive the combination of fedratinib and CC-486, or a placebo, to compare the effects. The study will be conducted in two phases. In the first phase, the focus will be on determining how safe and tolerable the combination is for patients. In the second phase, the study will assess how well the treatment works in terms of achieving the best possible response, which could include clinical improvement, partial remission, or complete remission of the disease. Throughout the study, participants will undergo regular check-ups, including physical exams and laboratory tests, to monitor their health and the effects of the treatment.

The study aims to gather information over a period of time to understand the duration of response to the treatment and any changes in symptoms associated with myelofibrosis. It will also look at how the treatment affects the size of the spleen, a common issue in myelofibrosis, and track the time until any disease progression or relapse occurs. The study is expected to continue until 2027, providing valuable insights into the potential benefits of combining fedratinib and CC-486 for patients with this challenging condition.

Participants in the study will receive either TP-3654 alone or in combination with momelotinib. The study will be conducted in two phases. In the first phase, researchers will determine the appropriate dose of TP-3654, both as a standalone treatment and in combination with momelotinib. In the second phase, the study will assess the preliminary effects of these treatments on the disease. Throughout the study, participants will be monitored for any side effects and changes in their condition.

The study aims to provide valuable information on how these treatments can help manage myelofibrosis. Participants will take the medications orally and will be regularly assessed to track their response to the treatment. The study will also evaluate changes in symptoms and overall health status to understand the potential benefits of TP-3654 and its combination with momelotinib for patients with myelofibrosis.

The treatment in this study includes the use of several medications. One of the key drugs is Treosulfan, which is administered as a solution for infusion. This means it is given directly into the bloodstream through a vein. Other medications used in the study include Fludarabine Phosphate and Thiotepa, both of which are also given intravenously. These medications are used to prepare the body for the transplant by reducing the number of existing bone marrow cells and helping the new stem cells to grow.

Participants in the study will receive these treatments over a period of several days before the transplant. After the transplant, they will be monitored closely for a year to check for any signs of the disease returning or the body rejecting the new stem cells. The study will also look at other factors such as the recovery of blood cells, overall survival, and any complications that may arise during the first year after the transplant. This research is important for improving treatment options and outcomes for patients with myelofibrosis.

Participants in the study will receive either RVU120 or a combination of RVU120 and Ruxolitinib. The study will last for a period of up to 24 months. During this time, participants will be monitored to see how their condition responds to the treatment. The study will involve regular check-ups and assessments, including imaging tests like MRI or CT scans, to measure changes in the size of the spleen, which is often enlarged in myelofibrosis. The study will also look at other factors such as symptom improvement and overall health outcomes.

Throughout the trial, the safety and side effects of the treatments will be closely observed. Participants will be asked to report any changes in their symptoms or any new symptoms they experience. The trial aims to provide valuable information on the potential benefits and risks of using RVU120, alone or with Ruxolitinib, for treating myelofibrosis. This research could lead to new treatment options for patients with this condition.

The purpose of this study is to evaluate the long-term safety and potential benefits of pelabresib for patients who have already been receiving this treatment in previous studies. Participants will continue to take pelabresib in the form of a tablet, and their health will be monitored over time to assess any side effects and overall survival. The study will also look at how long patients continue to benefit from the treatment and how it affects their quality of life.

Throughout the study, patients will have regular check-ups to monitor their condition and any changes in their health. The study aims to provide valuable information about the safety and effectiveness of pelabresib for managing myeloproliferative neoplasms, helping to improve treatment options for these conditions in the future.

The study is divided into different parts. Initially, participants will receive increasing doses of KER-050 to determine the safest and most effective dose. This phase will help understand how well participants tolerate the treatment. In the next phase, the study will expand to include more participants to further assess the safety of the chosen dose. There is also a long-term extension part of the study to evaluate the ongoing safety of KER-050, with or without Ruxolitinib, over a longer period.

Participants in the study will receive either KER-050 alone or in combination with Ruxolitinib. The study will monitor the participants for any side effects and measure how the treatments affect their condition. The study aims to find out if these treatments can help manage Myelofibrosis symptoms, improve blood cell counts, and reduce the need for blood transfusions. The study will also look at changes in spleen size using imaging techniques like CT or MRI. The trial is expected to continue until 2029, providing valuable information on the long-term effects of these treatments.

Participants in this study will continue their treatment with ruxolitinib or its combinations as they have been doing in their previous studies. The study will monitor the frequency and severity of any side effects or adverse events that occur during the treatment. This information will help researchers understand the long-term safety of these medications and their combinations.

The study is open-label, meaning that both the participants and the researchers know which treatment is being administered. It is conducted at multiple centers, allowing for a diverse group of participants. The study aims to provide valuable data on the safety of these treatments, which can benefit future patients who may receive these medications. Participants will be assessed regularly to determine any clinical benefits they may experience from the continued treatment.

The purpose of the study is to see if adding navtemadlin can help reduce the size of the spleen and improve symptoms in patients with myelofibrosis. The trial will involve taking tablets of navtemadlin or a placebo along with ruxolitinib. Participants will be randomly assigned to one of the two groups, and neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This is known as a double-blind study, which helps ensure the results are unbiased.

Throughout the study, participants will have regular check-ups, including physical exams and tests like MRI or CT scans, to monitor changes in spleen size and symptoms. The study will also track any side effects or adverse events that occur. The trial is expected to last several years, with the aim of providing valuable information on whether navtemadlin can offer additional benefits to patients with myelofibrosis who have a suboptimal response to ruxolitinib.

The purpose of the study is to determine the best dose of KRT-232 when used with Ruxolitinib and to see if this combination can reduce the size of the spleen, an organ that can become enlarged in these conditions. The study will involve regular check-ups and assessments to monitor the safety and effectiveness of the treatment. Participants will take the medications and have their spleen size measured at various points during the study, including at the 24-week mark. The study will also look at other factors, such as changes in symptoms and the need for blood transfusions.

This trial is open-label, meaning both the researchers and participants know which treatment is being administered. The study is expected to continue until 2025, allowing researchers to gather comprehensive data on the treatment’s impact over time. Participants will be closely monitored for any side effects or changes in their condition throughout the study period.

Participants in the study will be randomly assigned to receive either Navtemadlin or the best available therapy, which is the most effective treatment currently available for their condition. The study will last for several weeks, and during this time, doctors will monitor the size of the spleen using imaging techniques like magnetic resonance imaging (MRI) or computed tomography (CT) scans. The study will also look at other factors, such as the symptoms experienced by participants and their need for blood transfusions.

The study aims to provide valuable information about the effectiveness of Navtemadlin in treating myelofibrosis, especially for those who have not had success with JAK inhibitors. By comparing the new treatment with existing therapies, researchers hope to find better ways to manage this challenging condition. Participants will be closely monitored throughout the study to ensure their safety and to gather important data on how the treatment affects their health.

The purpose of this study is to evaluate the long-term safety of luspatercept, including monitoring for any progression to more serious conditions such as acute myeloid leukemia (AML) or the development of other types of cancer. Participants in this study will receive luspatercept as a solution for injection, which is administered under the skin. The study is designed as an open-label, single-arm, rollover study, meaning all participants will receive the treatment without a comparison group receiving a placebo.

Throughout the study, participants will be monitored for any adverse events or changes in their condition. The study will also track overall survival and any new growths that may develop. The maximum treatment period for participants is up to 360 days, during which they will continue to receive the treatment and be regularly assessed by healthcare professionals. This study aims to provide valuable information on the long-term effects and safety of luspatercept for individuals with these blood disorders.

The purpose of the study is to compare the effectiveness and safety of luspatercept with a placebo in adults who are already receiving a type of medication called a JAK2 inhibitor as part of their standard treatment. Participants in the study will receive either luspatercept or a placebo, and their progress will be monitored over a period of time to see if they can become free from needing red blood cell transfusions for at least 12 weeks.

Throughout the study, participants will continue their usual treatment with the JAK2 inhibitor while receiving the study medication. The trial aims to provide valuable information on whether luspatercept can offer a significant benefit in managing anemia in patients with myelofibrosis, potentially improving their quality of life by reducing the frequency of blood transfusions needed.

The purpose of the study is to compare the overall survival of patients treated with Imetelstat versus those receiving the best available therapy. Participants in the study will be randomly assigned to receive either Imetelstat or one of the standard treatments, which may include medications like Danazol, Corticosteroids, Busulfan, Anagrelide, Cladribine, Hydroxycarbamide, Mercaptopurine, or other supportive care options. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments.

The study will take place over a period of time, with regular check-ups and assessments to monitor the participants’ health and response to the treatment. The main goal is to see if Imetelstat can help patients live longer compared to the current best available therapies. Participants will be closely monitored for any changes in their condition, including symptoms and spleen size, which is often affected in myelofibrosis. The study aims to provide valuable information that could lead to better treatment options for people with this challenging condition.

The purpose of the study is to evaluate the safety and tolerability of bomedemstat. Participants in this study have previously been involved in a bomedemstat clinical trial and have been receiving the medication for at least six months. The study will continue to monitor these participants to ensure the treatment remains safe and to observe any potential side effects. Participants will take the medication at home and will be required to swallow the capsules as directed.

Throughout the study, researchers will keep track of any adverse events, which are unwanted effects that may occur during treatment. They will also monitor whether participants need to stop the treatment due to these effects. For those with essential thrombocythemia or polycythemia vera, the study will look at how long the treatment continues to work effectively. Additionally, the study will observe if there is any progression to more serious conditions like myelodysplastic syndrome or acute myeloid leukemia. The study aims to provide valuable information on the long-term use of bomedemstat for these conditions.

The purpose of the study is to evaluate how well fedratinib works in reducing the size of the spleen, an organ that can become enlarged in people with myelofibrosis. Participants in the study will be randomly assigned to receive either fedratinib or one of the standard treatments. These standard treatments may include medications like ruxolitinib, glatiramer acetate, dimethyl fumarate, peginterferon alfa-2a, hydroxycarbamide, danazol, busulfan, or other therapies that are commonly used to manage myelofibrosis. Some participants may receive a placebo, which is a substance with no active medication.

The study will take place over a period of time, during which participants will have regular check-ups to monitor their health and the effects of the treatment. The main goal is to see if fedratinib can help reduce the spleen size by at least 35% compared to the other treatments. Participants will also be monitored for any changes in their symptoms and overall health. This study aims to provide more information on the effectiveness and safety of fedratinib for people with myelofibrosis who have previously been treated with ruxolitinib.

The purpose of the study is to evaluate the safety, tolerability, and how the body processes these medications. Participants will receive the medications in different combinations and doses, and their health will be monitored closely. The study will also look at how Navitoclax affects the heart’s electrical activity, which is measured by a test called an ECG (electrocardiogram). This is important to ensure that the medications do not cause any harmful effects on the heart.

Throughout the study, participants will undergo regular health checks, including physical exams and laboratory tests, to monitor their response to the treatment. The study aims to gather information on the potential benefits and any side effects of the medications, helping to improve treatment options for people with Myeloproliferative Neoplasms.

Participants in this study may receive Ruxolitinib alone, in combination with other cancer treatments, or continue with their existing cancer therapy. The study is designed to ensure that patients who are benefiting from Ruxolitinib can maintain their treatment regimen. The study will track the occurrence of any side effects or serious health events that may arise during the treatment period.

The study is open-label, meaning that both the researchers and participants know which treatment is being administered. This trial will continue until 2026, providing ongoing access to the medication for those who are already benefiting from it. Participants will be required to attend scheduled visits and follow the treatment plan as outlined by the study protocol.

The purpose of the study is to evaluate how well selinexor works on its own in treating myelofibrosis. Participants in the study will take selinexor orally for a period of up to 105 days. During this time, they will have regular check-ups to monitor their health and see how the treatment is affecting their condition. The study will also compare the effects of selinexor with those of a placebo, which is a substance with no active medication, to better understand its effectiveness.

Throughout the study, participants will undergo various assessments, including imaging tests like MRI or CT scans, to measure changes in their spleen size and other health indicators. The study aims to gather information on the overall response to the treatment, including any changes in symptoms and side effects. This research will help determine if selinexor is a beneficial treatment option for people with myelofibrosis who have not been treated with JAK inhibitors before.

The purpose of this study is to provide extended access to momelotinib and to assess its long-term safety for patients who are already receiving this treatment and have not experienced a worsening of their disease. Participants in the study will continue to take the medication as they have been, and their health will be monitored over time to ensure the treatment remains safe and effective.

Throughout the study, researchers will keep track of any side effects that occur, as well as how serious they are and whether they are related to the medication. They will also look at how long patients live without their disease getting worse and whether they remain free from developing leukemia. This information will help determine the long-term safety and benefits of using momelotinib for treating myelofibrosis.

The purpose of the study is to compare the effects of the combination of selinexor and ruxolitinib with a placebo and ruxolitinib in patients with myelofibrosis. The study will look at how well the treatment reduces the size of the spleen, which is often enlarged in myelofibrosis, and how it affects symptoms and anemia, a condition where there is a lack of healthy red blood cells. The study will also monitor overall survival and response rates, which include complete and partial responses to the treatment.

Participants in the study will receive the treatment over a period of time, with regular assessments to monitor their response to the medication and any side effects. The study will use imaging techniques like MRI or CT scan to measure changes in spleen size and will assess symptoms using a specific form designed for myelofibrosis. The study is expected to continue until 2028, with recruitment starting in December 2023.

The purpose of the study is to assess the safety and tolerability of these treatments. The study will be conducted in two parts. In the first part, the focus will be on finding the right dose of BMS-986158 when used with Ruxolitinib or Fedratinib. In the second part, the study will further explore the safety of these combinations and also test BMS-986158 as a standalone treatment. Participants will be monitored for any side effects and how well they tolerate the medications.

Throughout the study, participants will undergo regular assessments, including imaging tests like MRI or computed tomography (CT) scans, to measure changes in their condition. The study aims to provide valuable information on how these treatments can be used to manage myelofibrosis, potentially offering new options for patients with this challenging disease.

The purpose of this study is to continue evaluating the safety of Itacitinib for participants who are experiencing clinical benefits from this treatment. Participants will continue to receive the medication in tablet form, taken orally, as part of their ongoing care. The study is designed to monitor any side effects or adverse events that may occur while participants are on this medication.

Throughout the study, participants will have scheduled visits to ensure their treatment is progressing safely and effectively. The study aims to provide a seamless transition for those who have been benefiting from Itacitinib in previous trials, allowing them to continue their treatment under careful observation. The study is expected to run until 2027, ensuring long-term support and monitoring for participants.

The study is divided into two phases. In the first phase, the focus is on determining the safety of tasquinimod and finding the right dose that can be used in the second phase. The second phase aims to evaluate how well tasquinimod works in reducing the size of the spleen, which is often enlarged in patients with myelofibrosis. This is measured using imaging techniques like MRI or CT scan after 24 weeks of treatment.

Participants in the study will take tasquinimod once daily and will be monitored for any side effects and changes in their condition. The study will also look at other outcomes, such as overall survival, changes in symptoms, and the need for blood transfusions. The trial is expected to continue until 2030, with recruitment starting in 2024.

The purpose of the study is to evaluate how effective this combination therapy is for patients with Myelofibrosis who have not responded well to previous treatments known as JAK-inhibitors. Participants in the study will receive the combination of Fedratinib and Nivolumab over a period of time, and their response to the treatment will be monitored. The study will look at various outcomes, such as the improvement in symptoms, the need for blood transfusions, and overall quality of life.

Throughout the study, the safety of the treatment will be closely observed, including any side effects that may occur. The trial will also assess how the treatment affects the progression of the disease and the overall survival of the participants. This research aims to provide valuable insights into the potential benefits of combining Fedratinib and Nivolumab for treating Myelofibrosis.

The purpose of the study is to determine how well selinexor works compared to the physician’s choice in patients who have already received treatment for myelofibrosis. The study will involve regular check-ups and assessments to monitor the effects of the treatment. Participants will be randomly assigned to one of the two treatment groups and will continue with their assigned treatment for a specified period. The study will also look at how the treatment affects symptoms and overall health, including any changes in spleen size, which is often enlarged in myelofibrosis.

Throughout the study, participants will be closely monitored for any side effects or changes in their condition. The study aims to provide valuable information on the potential benefits of selinexor for patients with myelofibrosis, helping to guide future treatment options. The trial is designed to ensure the safety and well-being of all participants while gathering important data on the effectiveness of the treatment.

The purpose of the study is to evaluate how well Pacritinib works in reducing the size of the spleen and improving symptoms in patients with myelofibrosis. The study will last for a period of 24 weeks, during which patients will receive either Pacritinib or one of the physician’s choice therapies. Throughout the study, patients will undergo regular assessments, including imaging tests like MRI or CT scans, to measure changes in spleen size and symptom severity. The study aims to determine if Pacritinib can achieve a significant reduction in spleen volume and improve the overall symptom score compared to the other treatments.

Participants in the study will be monitored for any side effects or adverse events, and their overall health will be assessed through various tests and evaluations. The study will also track the time it takes for any significant health changes to occur, such as improvements in symptoms or any serious health issues. The trial is expected to provide valuable information on the effectiveness and safety of Pacritinib for patients with severe thrombocytopenia due to myelofibrosis.